HomeCompareABMD vs CHD

ABMD vs CHD: Dividend Comparison 2026

ABMD yields 0.52% · CHD yields 1.27%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 CHD wins by $5.9K in total portfolio value
10 years
ABMD
ABMD
● Live price
0.52%
Share price
$381.02
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.4K
Annual income
$54.31
Full ABMD calculator →
CHD
CHD
● Live price
1.27%
Share price
$93.91
Annual div
$1.19
5Y div CAGR
23.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$26.4K
Annual income
$1,292.51
Full CHD calculator →

Portfolio growth — ABMD vs CHD

📍 CHD pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodABMDCHD
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ABMD + CHD cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ABMD pays
CHD pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ABMD
Annual income on $10K today (after 15% tax)
$44.62/yr
After 10yr DRIP, annual income (after tax)
$46.16/yr
CHD
Annual income on $10K today (after 15% tax)
$107.94/yr
After 10yr DRIP, annual income (after tax)
$1,098.63/yr
At 15% tax rate, CHD beats the other by $1,052.47/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ABMD + CHD for your $10,000?

ABMD: 50%CHD: 50%
100% CHD50/50100% ABMD
Portfolio after 10yr
$23.4K
Annual income
$673.41/yr
Blended yield
2.88%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on CHD right now

ABMD
Analyst Ratings
8
Buy
10
Hold
Consensus: Hold
Altman Z
68.8
Piotroski
5/9
CHD
Analyst Ratings
18
Buy
15
Hold
1
Sell
Consensus: Buy
Price Target
$98.40
+4.8% upside vs current
Range: $82.00 — $110.00
Altman Z
4.9
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ABMD buys
0
CHD buys
0
No recent congressional trades found for ABMD or CHD in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricABMDCHD
Forward yield0.52%1.27%
Annual dividend / share$2.00$1.19
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%23.1%
Portfolio after 10y$20.4K$26.4K
Annual income after 10y$54.31$1,292.51
Total dividends collected$535.00$5.5K
Payment frequencyquarterlyquarterly
SectorStockConsumer Staples
Analyst consensusHoldBuy

Year-by-year: ABMD vs CHD ($10,000, DRIP)

YearABMD PortfolioABMD Income/yrCHD PortfolioCHD Income/yrGap
1← crossover$10,752$52.49$10,856$156.32$104.00CHD
2$11,558$52.75$11,811$195.24$253.00CHD
3$12,420$52.99$12,883$244.38$463.00CHD
4$13,343$53.22$14,091$306.64$748.00CHD
5$14,330$53.43$15,463$385.88$1.1KCHD
6$15,387$53.63$17,033$487.17$1.6KCHD
7$16,518$53.82$18,843$617.36$2.3KCHD
8$17,728$53.99$20,947$785.72$3.2KCHD
9$19,023$54.16$23,419$1,004.91$4.4KCHD
10$20,409$54.31$26,350$1,292.51$5.9KCHD

ABMD vs CHD: Complete Analysis 2026

ABMDStock

Abiomed, Inc. engages in the research, development, and sale of medical devices to assist or replace the pumping function of the failing heart. It also provides a continuum of care to heart failure patients. The company offers Impella 2.5, a percutaneous micro heart pump with integrated motor and sensors; and Impella CP, a device for use by interventional cardiologists to support patients in the cath lab, as well as by cardiac surgeons in the heart surgery suite. It also provides Impella 5.0, Impella LD, and Impella 5.5, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite; Impella RP, a percutaneous catheter-based axial flow pump; Impella SmartAssist platform that includes optical sensor technology for improved pump positioning and the use of algorithms that enable improved native heart assessment during the weaning process; Impella Connect, a cloud-based technology that enables secure and remote viewing of the automated impella controller for physicians and hospital staffs; and OXY-1 System, a portable external respiratory assistance device. In addition, the company is developing Impella ECP, a pump for blood flow of greater than three liters per minute; Impella XR Sheath, a sheath that expands and recoils allowing small bore access and closure with Impella heart pumps; Impella BTR, a percutaneous micro heart pump with integrated motors and sensors; and preCARDIA, a catheter-mounted superior vena cava therapy system designed to rapidly treat acutely decompensated heart failure. Abiomed, Inc. sells its products through direct sales and clinical support personnel in the Germany, France, United States, Japan, Europe, Canada, Latin America, the Asia-Pacific, and the Middle East. The company was founded in 1981 and is headquartered in Danvers, Massachusetts. As of December 22, 2022, Abiomed, Inc. operates as a subsidiary of Johnson & Johnson.

Full ABMD Calculator →

CHDConsumer Staples

Church & Dwight Co., Inc. develops, manufactures, and markets household, personal care, and specialty products. It operates through three segments: Consumer Domestic, Consumer International, and Specialty Products Division. The company offers cat litters, carpet deodorizers, laundry detergents, and baking soda, as well as other baking soda based products under the ARM & HAMMER brand; condoms, lubricants, and vibrators under the TROJAN brand; stain removers, cleaning solutions, laundry detergents, and bleach alternatives under the OXICLEAN brand; battery-operated and manual toothbrushes under the SPINBRUSH brand; home pregnancy and ovulation test kits under the FIRST RESPONSE brand; depilatories under the NAIR brand; oral analgesics under the ORAJEL brand; laundry detergents under the XTRA brand; gummy dietary supplements under the L'IL CRITTERS and VITAFUSION brands; dry shampoos under the BATISTE brand; water flossers and replacement showerheads under the WATERPIK brand; FLAWLESS products; cold shortening and relief products under the ZICAM brand; and oral care products under the THERABREATH brand. Its specialty products include animal productivity products, such as MEGALAC rumen bypass fat, a supplement that enables cows to maintain energy levels during the period of high milk production; BIO-CHLOR and FERMENTEN, which are used to reduce health issues associated with calving, as well as provides needed protein; and CELMANAX refined functional carbohydrate, a yeast-based prebiotic. The company offers sodium bicarbonate; and cleaning and deodorizing products. It sells its consumer products through supermarkets, mass merchandisers, wholesale clubs, drugstores, convenience stores, home stores, dollar and other discount stores, pet and other specialty stores, and websites and other e-commerce channels; and specialty products to industrial customers and livestock producers through distributors. The company was founded in 1846 and is headquartered in Ewing, New Jersey.

Full CHD Calculator →
📬

Get this ABMD vs CHD comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ABMD vs SCHDABMD vs JEPIABMD vs OABMD vs KOABMD vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.